Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
Maricel G Miguelino, Jerry S Powell Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, CA, USA Abstract: Hemophilia B is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), with an incidence of approximat...
Main Authors: | Miguelino MG, Powell JS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-08-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/clinical-utility-and-patient-perspectives-on-the-use-of-extended-half--peer-reviewed-article-PPA |
Similar Items
-
Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
by: Andrea Aiello, et al.
Published: (2020-07-01) -
Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
by: Astermark J, et al.
Published: (2021-07-01) -
Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
by: Simpson ML, et al.
Published: (2019-11-01) -
Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01) -
Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)